L-Carnitine (Injectable)
← Back to LibraryCarnitine deficiency and transport of fatty acids into mitochondria.
Research Summary
- Evidence
- Strong for deficiency; limited for fitness injections
- Primary research
- Medical levocarnitine research, with important route and population differences.
- Research focus
- Carnitine deficiency and transport of fatty acids into mitochondria.
- Mechanism
- Supports long-chain fatty-acid transport for energy metabolism.
- Evidence limits
- Evidence for medical IV treatment does not validate IM/SC fat-loss or performance protocols.
Evidence
What is L-Carnitine?
L-Carnitine is a naturally occurring amino-acid derivative that helps move long-chain fatty acids into mitochondria, where they can be used to make energy. It is part of the transport system that helps fat reach the part of the cell where it can be used as fuel.
Injectable pharmaceutical L-Carnitine is usually called levocarnitine. An FDA-approved brand example is CARNITOR. L-Carnitine is not a peptide, a hormone, a stimulant, a GLP-1 agonist or a growth-hormone secretagogue.
How well studied is it?
L-Carnitine is well studied medically, but not for modern fitness injections. It has been studied in humans for decades, and an FDA-approved injectable version exists. There is an important difference between medical IV levocarnitine and the IM or SC L-Carnitine used in fitness and peptide communities for fat loss, energy or performance.
The strongest human evidence is for treating carnitine deficiency, including certain inherited metabolic disorders and deficiency in people receiving hemodialysis. The FDA-approved injectable route is IV.
Being necessary for fat metabolism does not mean that taking more L-Carnitine automatically causes more fat loss. For someone who is deficient, replacing carnitine can be medically important. For a healthy person who already has enough carnitine, the benefit of injecting extra L-Carnitine is much less certain.
Evidence level
| Evidence type | Rating | Notes |
|---|---|---|
| Approved-label human evidence | Strong (carnitine deficiency) | An FDA-approved IV levocarnitine product has clear human dosing, safety and pharmacokinetic information. |
| Human clinical research | Extensive, but depends on condition and route | Carnitine deficiency, dialysis, exercise, muscle loading, metabolism and body composition. |
| Observational human evidence | Supporting | Decades of medical use provide additional safety and treatment experience. |
| Animal / cell evidence | Extensive | Useful for understanding how carnitine transport and mitochondria work. |
| Mechanistic evidence | Strong | Carnitine's role in transporting long-chain fatty acids into mitochondria is well established. |
| Fat loss / exercise research | Mixed | Mostly oral or IV research, not modern injection protocols. |
| IM/SC fitness protocols | Limited | Not validated to the same level as clinical IV levocarnitine. |
| Community / anecdotal evidence | Common, but much weaker | Not equivalent to clinical evidence. |
Overall evidence rating
Strong human evidence for deficiency treatment; much weaker evidence for modern IM/SC fitness use.
- Strong evidence for: normal fatty-acid transport, IV levocarnitine pharmacology, treatment of some carnitine deficiencies, dialysis-related carnitine replacement, increasing blood carnitine, and insulin helping muscle take up carnitine.
- Some human evidence for: increasing muscle carnitine, exercise fuel use, modest body-weight and fat-mass changes, and some metabolic outcomes.
- Limited or unproven for: high-dose IM bodybuilding protocols, daily SC fat-loss protocols, rapid fat loss, belly-fat targeting, GLP-1 fatigue treatment, fasted superiority, pre-workout superiority, two-week muscle saturation, and fixed 8–16 week cycles.
Primary research focus
- Best established: carnitine deficiency, fatty-acid transport, inherited metabolic disorders, dialysis-related carnitine deficiency.
- Also studied: muscle carnitine uptake, exercise fuel use, insulin-assisted muscle loading, body composition, metabolic health.
- Not established: major standalone fat loss, spot fat loss, bodybuilding enhancement, guaranteed energy improvement, treatment of GLP-1 fatigue.
What may it help with?
Strong human evidence
- Carnitine deficiency: levocarnitine can replace carnitine in people whose levels are too low because of certain inherited metabolic disorders.
- Dialysis-related carnitine deficiency: people receiving hemodialysis can lose carnitine. Repeated IV levocarnitine reliably raises blood carnitine levels in this population.
- Normal fat transport: carnitine's role in helping long-chain fatty acids reach mitochondria is well established.
Some human evidence
- Increasing carnitine inside muscle: muscle carnitine can be increased under the right conditions. One 24-week study used oral L-carnitine L-tartrate with carbohydrate and increased muscle carnitine by about 21%.
- Exercise fuel use: there is some evidence that carnitine availability can affect how the body uses fat and carbohydrate during exercise. That does not prove injectable L-Carnitine is a powerful performance enhancer.
- Body weight and fat mass: a review of randomized studies found a small average reduction in body weight, BMI and fat mass with L-Carnitine supplementation, especially in people with overweight or obesity. Most of that research was not based on modern IM or SC injection protocols.
What has it not been proven to help with?
Injectable L-Carnitine has not been proven to reliably cause:
- rapid fat loss or large weight loss on its own
- fat loss without a calorie deficit
- belly-fat targeting, or fat loss at the injection site
- major muscle growth
- a dramatic increase in resting metabolism
- guaranteed energy improvement
- reliable athletic-performance improvement
- prevention of GLP-1 fatigue
- replacement of diet or exercise
L-Carnitine is needed for normal fat metabolism. That does not mean more L-Carnitine automatically means more fat burned.
Dosing evidence
Clinical / FDA-approved injectable dosing
There is not one universal clinical dose. The FDA-approved CARNITOR injection is given intravenously.
| Indication | Label dose | Route | Frequency / timing |
|---|---|---|---|
| Certain inherited metabolic disorders | 50 mg/kg | IV, as a slow 2–3 minute injection or infusion | Depends on the medical situation. During a severe metabolic crisis the label allows more frequent dosing under medical supervision. |
| Hemodialysis-related deficiency | Starting dose 10–20 mg/kg dry body weight | IV | After dialysis. The dose can be adjusted based on blood carnitine levels. |
Clinical monitoring in metabolic disorders can include blood carnitine, blood chemistry, vital signs and overall clinical response.
Human exercise research
One acute human experiment used 3 g IV about 40 minutes before exercise. This was a research experiment, not an approved fitness protocol.
Research-community dosing
Community injection protocols look very different from the FDA-approved protocol. They are documented here because people use them; they have not been validated in controlled human trials.
PeptideFox (IM). PeptideFox material describes 500 mg IM, 1–3 times per week. It also describes a loading approach of 1,000 mg daily for about 14 days, followed by maintenance at 500 mg 2–3 times weekly.
PeptideDosages (SC). PeptideDosages describes a lower-dose SC approach:
- Weeks 1–2: 50 mg SC daily
- Week 3 onward: 100 mg SC daily
- Higher community doses: up to 150–200 mg daily
- Duration: about 8–16 weeks
Evidence check for community protocols
| Protocol element | Status |
|---|---|
| IM route | Community use, not the approved route |
| 500 mg dose | Community protocol |
| 1–3 times weekly | Community protocol |
| 14-day loading | Community convention |
| Carbohydrate pairing | Basic idea has human support |
| Full muscle loading in about 14 days | Not proven in a matching human IM trial |
| SC route, 50 to 100 mg increase, 8–16 week cycle, 150–200 mg higher dose | Not established by a matching randomized human study |
There is no healthy-human trial proving that 500 mg IM is the best dose, that 1,000 mg IM is the best loading dose, that 100 mg SC is the best daily dose, that daily SC is better than intermittent IM, or that a 14-day loading phase is necessary.
Protocol comparison
| Source | Dose | Route | Frequency | Duration | Evidence |
|---|---|---|---|---|---|
| CARNITOR, metabolic disorders | 50 mg/kg | IV | Depends on condition | Clinical | FDA label |
| CARNITOR, dialysis | 10–20 mg/kg | IV | After dialysis | Clinical | FDA label |
| Acute exercise study | 3 g | IV | Single experimental dose | Acute | Human research |
| PeptideFox | 500 mg | IM | 1–3x/week | Variable | Community |
| PeptideFox loading | 1,000 mg | IM | Daily | ~14 days, then maintenance | Community |
| PeptideDosages | 50–100+ mg | SC | Daily | ~8–16 weeks | Community |
There is no single dose that all sources agree on. What is clear: IV levocarnitine has tested clinical dosing, and separate IM and SC community protocols exist. These should not be blended into one "standard dose".
Frequency
- Clinical, hemodialysis: usually given after dialysis sessions. Some clinical studies used IV levocarnitine three times per week after dialysis.
- Clinical, metabolic disorders: frequency depends on the condition. During a serious metabolic crisis, IV doses may be given much more often.
- Community, IM: commonly 1–3 times per week.
- Community, SC: commonly once daily.
The best-supported fitness frequency is unknown. No controlled human study has shown that daily SC or intermittent IM is the better body-composition protocol.
Timing
For dialysis, the approved dose is given after the dialysis session. Outside specific medical instructions, there is no general FDA requirement to take injectable L-Carnitine fasted, in the morning, before or after exercise, or with carbohydrates.
Two community approaches are common. Some protocols use L-Carnitine in the morning or before exercise while fasted. Others combine it with carbohydrates because insulin can help move carnitine into muscle.
| Timing approach | Evidence verdict |
|---|---|
| Carbohydrate / insulin-assisted muscle uptake | Supported in human research |
| Exact injectable carbohydrate protocol | Not proven |
| Fasted dosing | Makes biological sense, but better fat loss has not been proven |
| Pre-workout timing | Studied experimentally, but not shown to be superior |
Duration and cycling
Clinically there is no universal cycle. Treatment lasts as long as carnitine replacement is medically needed, and repeated IV treatment has been studied over weeks and months. One important muscle-loading study lasted 24 weeks.
Community schedules include 8–16 weeks of daily SC use, a 14-day IM loading phase followed by maintenance, and ongoing intermittent IM use.
No receptor-reset cycle has been established. L-Carnitine is not a drug that repeatedly switches a receptor on, and there is no proven reason for 5 days on / 2 days off, 8 weeks on / 4 weeks off, a receptor reset or a mandatory washout.
Dose escalation / titration
Some community protocols increase from 50 mg to 100 mg to 150 mg, or similar. No matching randomized human study shows this is the ideal way to increase L-Carnitine. Starting lower may make sense simply to see how well someone tolerates it, which is different from a medically proven titration schedule.
Does the route match the research?
| Use | Route |
|---|---|
| FDA-approved CARNITOR | IV |
| Human exercise research | IV |
| PeptideFox community use | IM |
| PeptideDosages community use | SC |
The approved clinical route and modern fitness routes are not the same. IM and SC fitness protocols are not the FDA-approved route or dose.
Expected results timeline
Clinical research
- Immediately after IV dosing: blood carnitine levels rise quickly.
- Within the first week: in a dialysis study using 20 mg/kg after dialysis three times per week, blood carnitine levels were already substantially higher after the first week.
- 8–24 weeks: repeated treatment kept blood carnitine levels raised over longer periods.
- Around 24 weeks: getting more carnitine into muscle takes much longer than raising blood levels. In one human study using L-Carnitine plus carbohydrate, muscle carnitine increased significantly after 24 weeks.
Blood levels can rise quickly. Muscle loading and longer-term body-composition changes can take weeks to months.
Commonly reported community timeline
- Within hours: the compound is available in the body.
- 1–2 weeks: some people report changes in energy.
- 4–8 weeks: some report body-composition changes when diet and exercise are also controlled.
These are community reports, not averages from controlled IM or SC trials. Claims that muscle becomes "fully loaded" after about two weeks of injections are also community claims.
Protocol logic check
| Protocol question | Verdict |
|---|---|
| Does L-Carnitine help transport fatty acids? | Yes, well established |
| Is the FDA-approved injection IV? | Yes |
| Is 50 mg/kg IV a real clinical dose? | Yes, for certain metabolic disorders |
| Is 10–20 mg/kg after dialysis supported? | Yes |
| Is 500 mg IM 1–3x/week proven? | Community protocol |
| Is 50–100 mg SC daily proven? | Community protocol |
| Is a 14-day loading phase necessary? | Not proven |
| Does fasted dosing make sense? | Possible, but not proven better |
| Can insulin help muscle take up carnitine? | Yes |
| Is one exact carb-paired injection protocol proven? | No |
| Is pre-workout timing proven better? | No |
| Does it need 5 days on / 2 off? | No proven reason |
| Does it need an 8–16 week cycle? | No proven biological reason |
| Does it need a receptor reset? | No |
| Does injecting into belly fat burn belly fat? | No evidence |
| Can every vial use the same 2–4 week storage rule? | No |
| Does injectable L-Carnitine make zero TMAO? | Not established |
Does daily dosing make sense?
Daily treatment can make sense in some medical deficiency states, and daily SC dosing is common in community protocols. No controlled healthy-person study has shown that daily SC L-Carnitine works better than intermittent IM L-Carnitine for fat loss or performance.
Does 1–3 times weekly make sense?
PeptideFox uses this frequency in its IM protocol, and three-times-weekly dosing also appears in dialysis research. These are different protocols. Dialysis studies used IV administration, weight-based dosing, people with a medical deficiency and dosing after dialysis. Community protocols use IM injections, fixed doses, generally non-deficient people, and fat-loss or performance goals.
Does fasted dosing make sense?
When fasted, the body tends to rely more heavily on fat for fuel, which gives fasted use some biological logic. L-Carnitine helps transport fatty acids, but it does not force stored body fat to be released. No strong human injection study has shown that fasted IM or SC L-Carnitine produces better fat loss.
Does taking it with carbohydrates make sense?
There is more evidence behind this idea. Human research shows that insulin can help skeletal muscle take up carnitine when blood carnitine is high, and a later 24-week study using L-Carnitine with carbohydrate increased muscle carnitine by about 21%. This does not prove that every injection needs exactly 60–80 g of carbohydrate, or that two weeks of carb-paired injections will fully load the muscle.
Pre-workout timing
One human experiment used 3 g IV L-Carnitine about 40 minutes before exercise, so pre-exercise use has been studied. That does not show that 200 mg SC or 500 mg IM pre-workout is ideal, or that taking it before exercise produces more long-term fat loss.
5 days on / 2 days off, 8–16 week cycles and washouts
L-Carnitine does not work by repeatedly stimulating a receptor, so there is no reason to assume weekends off "reset" how it works. There is no known event at week 8, 12 or 16 that makes it stop working or requires a break; 8–16 week schedules are a community convention, not a biological requirement. No 2-week washout, 4-week break or receptor recovery period has been established.
Does it need a receptor reset?
No. L-Carnitine is not a receptor agonist; it is part of normal metabolism and transport. The body can control how much carnitine enters cells, but that is not the same as a receptor becoming desensitized.
Does injecting into belly fat burn belly fat?
No evidence shows that injecting L-Carnitine into abdominal fat causes that area to lose more fat. L-Carnitine works through normal metabolism throughout the body.
Mechanism and pharmacokinetics
What does L-Carnitine target?
L-Carnitine does not work by switching one receptor on. It is part of the carnitine shuttle, which moves long-chain fatty acids into mitochondria, the cell's engines.
Pathway: fatty acids, then the L-Carnitine transport system, then mitochondria, then energy.
Important parts of this system include CPT-1, carnitine-acylcarnitine translocase and CPT-2. The body also uses transport proteins such as OCTN2 to move carnitine into cells. This mechanism is well established.
L-Carnitine helps the body use fatty acids that are already available. It does not tell fat cells to release stored body fat.
Human half-life
After one 20 mg/kg IV dose, the CARNITOR label reports a distribution half-life of about 0.6 hours and a terminal half-life of about 17 hours.
This does not mean another dose is needed every 17 hours. Blood half-life does not show how fast muscle loads with carnitine, the best IM or SC schedule, how quickly body composition changes, or when a maintenance injection should happen.
Blood levels vs muscle levels
L-Carnitine can rise quickly in the blood after an injection, but getting more carnitine into muscle can take much longer. Repeated IV treatment can raise blood carnitine considerably, but muscle does not absorb unlimited carnitine because the blood level is high: muscle uptake is controlled by the body.
What about TMAO?
Oral L-Carnitine can be broken down by gut bacteria into compounds that can eventually become TMAO. Injecting L-Carnitine avoids the first pass through the gut, which gives a reasonable basis for a different TMA/TMAO pattern. There is not enough route-specific human evidence to show that injectable L-Carnitine produces zero TMAO.
What studies have found
Clinical IV / dialysis research
In one nine-week study, people receiving hemodialysis were given 20 mg/kg IV three times per week after dialysis. Blood carnitine levels rose substantially.
This supports IV use, repeated post-dialysis dosing, correction of low blood carnitine, and three-times-weekly treatment in this specific medical setting. It does not support 500 mg IM for fat loss, 100 mg SC every day, pre-workout SC protocols or bodybuilding protocols.
Acute exercise research
One healthy-human experiment used 3 g IV L-Carnitine about 40 minutes before exercise to study its effects on exercise metabolism. It does not establish 200 mg SC or 500 mg IM as equivalent protocols, guaranteed extra fat burning, or a standard pre-workout dose.
Muscle carnitine loading research
A 24-week human study used L-Carnitine with carbohydrate and found about a 21% increase in muscle total carnitine. This shows that muscle carnitine can be increased, that insulin and carbohydrate availability can help, and that muscle loading can take months. It does not validate a 14-day IM loading protocol, full muscle saturation in two weeks, or one exact carbohydrate dose for injections.
Body weight / fat-mass research
A meta-analysis of human studies found a modest average effect on body weight, BMI and fat mass, especially in people with overweight or obesity. L-Carnitine may have a small body-composition effect in some people. The research does not show dramatic fat loss, rapid injection-based fat loss, spot reduction, or large results without diet or activity changes.
Three types of use that are often mixed together
- FDA-approved IV levocarnitine: a prescription medication with a tested formulation, IV administration, weight-based clinical dosing, human pharmacokinetic data, specific medical uses and product-specific handling instructions.
- Human research: studies of exercise metabolism, muscle uptake, insulin-assisted muscle loading, body composition and metabolic conditions, using oral and IV forms. These results do not automatically apply to IM or SC protocols.
- Community injection protocols: higher-dose IM injections, lower-dose daily SC injections, fasted use, pre-workout use, carbohydrate pairing, and loading and maintenance phases. These are community protocols, not established clinical protocols.
Storage
CARNITOR injection
| Property | Detail |
|---|---|
| Compound | Levocarnitine |
| Strength | 1 g per 5 mL |
| Concentration | 200 mg/mL |
| Form | Sterile liquid solution |
| Route | IV only |
| Vial | Single dose |
| Preservative | None |
- Store unopened vials at controlled room temperature.
- Avoid excessive heat.
- Do not freeze.
- Once opened, discard any unused portion, because the vial contains no preservative.
Compounded and community injectable L-Carnitine
Not every product sold as injectable L-Carnitine is the same. A compounded IM vial, SC multidose vial, lyophilized research product or vial mixed with bacteriostatic water may have a completely different concentration, ingredients, preservative, storage needs and expiration after opening. CARNITOR storage rules do not automatically apply to them, and a rule such as "injectable L-Carnitine lasts 2–4 weeks after mixing" cannot be applied to every product. Storage instructions for the exact product and formulation apply.
Contraindications & cautions
Formal contraindications
The FDA label lists no known contraindications. That does not mean there are no important cautions.
Important cautions
- Seizure history: new or worsening seizures have been reported.
- Warfarin: INR may increase.
- Previous serious allergic reaction: serious allergic reactions have occurred.
- Pregnancy: good controlled pregnancy studies are limited.
- Breastfeeding: risks and benefits need careful consideration.
- Severe kidney disease: the label warns about buildup of TMA/TMAO from long-term high-dose oral L-Carnitine in severe kidney dysfunction. Kidney disease is not a blanket contraindication to injectable L-Carnitine; IV levocarnitine is used medically in dialysis patients.
Possible side effects
Label-supported effects
Reported effects include nausea, vomiting, body odor, stomach irritation, diarrhea, headache, dizziness, injection-site reactions and pain.
Seizures
Seizures have been reported in people with and without a previous seizure history. People with seizure disorders have also reported more frequent or more severe seizures.
Serious allergic reactions
Reported reactions include anaphylaxis, throat swelling and bronchospasm.
Warfarin interaction
Levocarnitine may increase INR in people taking warfarin. Closer INR monitoring may be needed after starting L-Carnitine or changing the dose.
Regulatory status
| Question | Status |
|---|---|
| FDA approved? | Yes, prescription injectable levocarnitine |
| FDA-approved injectable route | IV. CARNITOR injection is labeled "For intravenous use only." |
| Approved for | Carnitine deficiency caused by certain inherited metabolic disorders; prevention and treatment of carnitine deficiency in people with end-stage kidney disease receiving dialysis |
| FDA approved for IM bodybuilding use? | No |
| FDA approved for SC fat-loss use? | No |
| FDA approved for ordinary weight loss, body recomposition, sports performance or GLP-1 fatigue? | No |
FDA-approved injectable levocarnitine is IV. IM and SC L-Carnitine protocols are community or off-label protocols and are not the approved clinical route or dose.
Compatibility
Stack / pairing logic
| Pairing | Logic | Verdict |
|---|---|---|
| Carbohydrates / insulin | Human research supports insulin helping muscle take up carnitine. | Basic idea supported; no proven exact injection-and-carb protocol |
| GLP-1 agonists | Work through different pathways. | Not redundant, but no good evidence that L-Carnitine prevents GLP-1 fatigue or improves GLP-1 weight loss |
| MOTS-c | Different metabolic pathways. | Makes sense on paper; not properly tested in humans |
| NAD+ | Different roles in energy metabolism. | Possible complementary effects; no validated combination protocol |
| SS-31 | Different mitochondrial mechanisms. | Possible complementary effects; combination unproven |
IV compatibility
Under the labeled conditions, CARNITOR can be mixed with 0.9% sodium chloride or Lactated Ringer's for IV use, under the product's specified conditions.
Sources
- DailyMed. CARNITOR (levocarnitine) injection, FDA-approved prescription-drug labeling. Supports the IV route, clinical dosing for metabolic disorders and dialysis-associated deficiency, human pharmacokinetics, seizure, hypersensitivity and warfarin warnings, formulation, single-dose vial handling, storage and IV compatibility. dailymed.nlm.nih.gov
- Natali et al. Acute IV L-carnitine during exercise. Human experimental research: 3 g IV about 40 minutes before exercise; does not establish an IM or SC performance protocol. pubmed.ncbi.nlm.nih.gov/8492714
- Stephens et al. Insulin and muscle L-carnitine uptake. Human mechanistic research: insulin can increase skeletal-muscle carnitine uptake when blood carnitine is high, and muscle uptake is regulated. pubmed.ncbi.nlm.nih.gov/16368715
- Wall et al. Chronic L-carnitine plus carbohydrate muscle loading. Human controlled research: 24 weeks, about 21% increase in muscle total carnitine; does not validate a 14-day IM loading protocol. pubmed.ncbi.nlm.nih.gov/21224234
- Talenezhad et al. L-carnitine and body composition: systematic review and meta-analysis of human studies. Modest average reductions in body weight, BMI and fat mass. pubmed.ncbi.nlm.nih.gov/32359762
- PeptideFox. Injectable L-carnitine. Community / practitioner protocol: 500 mg IM dosing, 1–3 times weekly use, loading approaches, fasted and pre-workout timing, carbohydrate pairing, community-reported timeline. peptidefox.com
- PeptideDosages. L-carnitine 200 mg vial dosage protocol. Community research protocol: 50 to 100 mg SC progression, daily SC use, higher doses of about 150–200 mg, 8–16 week framework, reconstitution and storage practices. peptidedosages.com